Table 5.
Budget impact analysis of the gradual increase of LINE usage in the treatment of meticillin-resistant S. aureus complicated skin and soft tissue infections
| Current cost | Cost after 1 year | Cost after 2 years | Cost after 3 years | |
|---|---|---|---|---|
| Inpatient pharmaceuticals | €5,305,213 | €5,220,891 | €5,145,002 | €5,262,737 |
| Difference | −€84,322 | −€160,211 | −€42,476 | |
| Inpatient medical | €23,891,005 | €23,782,036 | €23,696,418 | €23,585,504 |
| Difference | −€108,968 | −€194,586 | −€305,501 | |
| Total budget impact | €29,196,218 | €29,002,927 | €28,841,420 | €28,848,241 |
| Difference | −€193,291 | −€354,798 | −€347,977 | |